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Abstract  
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. The 
pathogenesis of AD is linked to the oligomerization and aggregation of the amyloid-
β peptide (A) into protein plaques in the brain. However, the role of these 
aggregates in the disease pathology remains largely unknown. An important 
hypothesis today is that neurotoxic oligomeric Aβ aggregates are responsible for 
cell death. And there might be interaction of neurotoxic oligomeric Aβ with other 
proteins in human biological fluids that might be involved in amyloid-β 
neurotoxicity. The project was aimed in identifying which proteins in human 
biological fluids interact with neurotoxic oligomeric form of Aβ.  
 
A proteomics approach has been developed in which stable oligomers formed by a 
modified Aβ peptide (Aβ42cc) have been used to capture protein ligands in human 
serum and cerebrospinal fluid (CSF). The captured proteins have then been 
separated by gel electrophoresis and characterized by mass spectrometry. Five 
proteins in human serum have been identified as Apolipoprotein A-I, 
Apolipoprotein E, Apolipoprotein A-IV, Vitronectin and Antithrombin III. Six CSF 
samples have been investigated of which three were from AD patients and three 
from healthy individuals. Four proteins in different CSF samples have been 
identified as Apolipoprotein A-I, Apolipoprotein E, Clusterin and Gelsolin. Our 
results show that there are interactions between Aβ42cc oligomers and other 
proteins in serum and CSF.  
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1. Introduction  
Alzheimer’s disease (AD) is the most common form of dementia in the elderly. More 
than 35 million people worldwide now have AD [1]. If the current numbers hold and 
no preventative treatments become available, more than 100 million people are 
expected to have AD worldwide by 2050 [2]. Current treatments of AD are limited 
and the available cures are not effective.  
The disease is characterized by the presence of two abnormal protein deposits: 
senile plaques and neurofibrillary tangles in the brain. The major component of the 
senile plaques is the amyloid β-peptide (Aβ) *3+, which is the proteolytic cleavage 
products of the amyloid precursor protein (APP) [4,5]. APP is a transmembrane 
(TM) polypeptide of 695-770 amino acid residues with three parts: a large 
extracellular N-terminal region, a TM region and cytoplasmic C-terminal domain [4]. 
Aβ originates from parts of the TM region of APP (figure 1A) [6]. APP undergoes 
enzymatic cleavage into two main pathways: nonamyloidogenic and amyloidogenic. 
In the nonamyloidogenic pathway, α-secretase cuts APP in the middle of Aβ region, 
which prevents Aβ generation (figure 1B). In the amyloidogenic pathway, β-
secretase cleaves APP just before the Aβ domain and produces differently sized Aβ 
peptides (figure 1C) [6]. The Aβ-peptide is 39-43 amino acid residues in length, 
among these, Aβ1-40 and Aβ1-42 are most abundant [7,8]. The Aβ1-42 peptide is most 
hydrophobic, fibrillogenic and more neurotoxic than Aβ1-40 [8]. Aβ peptides are 
produced both in healthy and AD brains. In healthy brain these peptides are usually 
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broken down and eliminated. Whereas in AD brain, the peptides undergo 
conformational changes and accumulate to form hard, insoluble plaques (figure 2). 
 
Figure 1. Amyloid precursor protein (APP) processing with Aβ generation.  
(A) The largest isoform (770 residues) of APP with extracellular domain, TM region and 
intracellular C-terminal domain. Aβ-peptide is partly embedded in TM part. APP 
undergoes enzymatic cleavage into two pathways, nonamyloidogenic and 
amyloidogenic. 
(B) In the nonamyloidogenic pathway, α-secretase cleaves APP within Aβ-peptide, which 
results in large soluble APP derivatives called sAPPα and a 83 residues carboxy-terminal 
fragment called APP-CTFα. The carboxy-terminal fragment is subsequently cleaved by -
secretase to generate a shortened p3 peptide. The remaining APP intracellular domain 
(AICD) is released into the cytoplasm. Since α-secretase cuts APP in the middle of the Aβ 
region this prevents Aβ generation. 
(C) In the amyloidogenic pathway, β-secretase cleaves APP just before the Aβ region, which 
results in soluble sAPPβ peptide. The remaining carboxy-terminal fragment, APP-CTFα or 
C99 is cleaved by -secretase that produces 42-43 residues Aβ-peptide. Similar to 
nonamyloidogenic pathway, ACID is released to cytoplasm.  
  
Beside AD, amyloidogenic peptides are also involved in several other diseases 
including Parkinson’s disease (PD), diabetes mellitus and systemic amyloidoses. Aβ 
peptides can form different conformational products, including soluble Aβ 
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oligomers and insoluble Aβ fibrils (figure 2) *7+.  In AD, the soluble Aβ oligomer 
aggregartes are more correlated with the pathogenesis than the deposition of 
insoluble fibrillar Aβ *9+.  
 
 
 
 
 
Figure 2. Aβ-aggregation in AD brain.  
Aβ-peptide produces in both healthy and Alzheimer’s brain. In Alzheimer’s brain, the self-
assembly of Aβ-peptide leads to Aβ aggregation and subsequently insoluble plaques 
formation. A hypothesis suggests Aβ aggregates via two pathways [17]: the β-sheet 
pathway, involving Aβ aggregation into soluble β-sheet oligomers and then fibril by cross-β 
packing and the coil pathway, involving aggregation of monomer or disordered low 
molecular weight oligomers into low molecular weight aggregates (not shown in figure). 
Neurotoxic Aβ-oligomers are formed via β-sheet pathway.  
 
The amyloid hypothesis and several studies suggest that oligomerization and 
aggregation of Aβ is linked to the pathogenesis of AD, but the mechanism is not 
fully understood yet. Extensive research still needs to address many questions 
including an understanding of the Aβ toxicity mechanism [7].  
Aβ oligomers might interact with other biomolecules in human biological fluids and 
such interactions might be involved in Aβ neurotoxicity. The presence of certain 
proteins, including immunoglobulins, antitrypsin, serum amyloid-P, acute-phase 
proteins, cell adhesion molecules and cytokines in the senile plaques of AD brain 
suggests that these proteins may be involved in the pathogenesis of AD [10,11]. 
These interactions can be specific or less specific. There might certain epitopes on 
Aβ oligomers that are capable of specific interactions with other cellular 
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components. Beside the specific interaction, unspecific interaction can also be 
directed by surface properties of Aβ oligomers, the hydrophobic surface of Aβ 
oligomers can be involved in non-specific interactions [12]. Human blood is the 
most valuable body fluid as blood proteins including albumin, immunoglobulin G 
and α1-anititrypsin have been purified and used in different therapies [13]. Along 
with blood, cerebrospinal fluid (CSF) is another important biological fluid. Blood and 
CSF components could be used as biomarkers of AD [14,15,16]. 
 
 
Figure 3. Engineering of Aβ peptide to Aβcc.  
(A) The wild type Aβ40 peptide with a β-hairpin conformation that is observed in complex 
with an affibody binding protein (left). Engineered Aβcc where the two alanine residues 
have been mutated to cysteines (Cys21/Cys30) that from a disulfide bond, and this 
disulfide bond locks the β-hairpin conformation therefore confirm Aβ oligomer 
stabilization (right). 
(B) Transmission electron microscopy images of oligomers of Aβ40cc (left) and of amyloid 
fibrils formed in presence of TCEP that reduce the cysteine residues and break the 
disulfide linkage (right). Figures from Sandberg et al. 2010 (figures used with permission) 
[17]. 
 
 
To study the interactions of Aβ oligomers with other components of blood serum 
and CSF, Aβ oligomers with a stable structure are required. Neurotoxic Aβ 
oligomers have been stabilized via protein engineering [17] and double cysteine 
mutated Aβ (Aβcc) can be produced in Escherichia coli (E. coli) by co-expression 
with ZAβ3 affibody [7]. Histidine tagged ZAβ3 affibody binds to a hairpin conformation 
of Aβcc and produces Aβcc with an intramolecular disulfide bond so as to avoid its 
aggregation and remain as a stable complex with affibody (figure 3A) [17]. Different 
proteomics approaches have been using to study protein-protein interactions. 
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Currently most of the proteomics technologies are based on mass spectrometry 
(MS) in combination with liquid chromatography and gel electrophoresis [18,19].  
The work plan of this project has been divided into two parts where one is to 
produce pure Aβ42cc oligomers. An engineered Aβ-affibody complex (Aβ42cc:ZAβ3, 
constructed in Prof.Torleif Härd’s group at department of molecular biology, SLU) 
has been overexpressed, purified and separated using existing protocols [8]. Aβ42cc 
oligomers were produced by dialysis of peptide in denaturing solution against 
sodium phosphate buffer at pH 7.2. The other part of the project has been to study 
the interactions of Aβ42cc oligomers with other proteins in human serum and CSF. 
The main focus of this second part was to develop a capturing method to capture 
protein ligands in human serum and CSF. After successful developing and capturing, 
the captured proteins have been separated by gel electrophoresis and analyzed by 
MS. We have identified five proteins in serum that are fished out with Aβ42cc 
oligomers. For the identification and comparison of binding proteins in CSF, we 
used six different samples of which three are from different AD patients and the 
other three are from non-AD individuals. Four proteins that were fished out with 
Aβ42cc oligomers from different CSF samples have been identified.   
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2. Materials and Methods 
2.1 Protein expression 
A mutant Aβ protein (Aβ42cc) was used in this project. The double cysteine mutated 
Aβ (Aβ42cc) was produced in E. coli by co-expression with ZAβ3 affibody. The 
Aβ42cc:ZAβ3 complex was constructed in a bacterial plasmid called pACYCDuet-1 
where genes for Aβ42cc and affibody ZAβ3 have been introduced under separate 
promoters and the construct has been transformed in to E. coli Orgami B cells that 
are stored as glycerol stock. The affibody ZAβ3 protein is tagged with six histidine 
residues [8]. Cell culture for overexpression was started from a glycerol stock. A 
pre-culture was grown overnight in Terrific Broth (TB) medium (appendix 1) at 37 :C 
with continuous shaking at 120 rpm. In addition to the TB medium, the pre-culture 
also contained 110 ml/L of 1 M (10X) potassium phosphate buffer (appendix 1), 34 
mg/L chloramphenicol, 12.5 mg/L tetracyclin and 15 mg/L kanamycin. The pre-
culture was transferred to the main culture, as 75 ml pre-culture/liter main culture. 
The main culture contained TB medium, potassium phosphate and all three 
antibiotics in the same concentrations used in pre-culture. The culture was grown 
at 37 :C with shaking at 120 rpm. The optical density (OD) at 600 nm was monitored 
and when the OD reached approximately 0.8 AU, the expression was induced by 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 
1 mM. The cells were harvested by centrifuging at 4500 rpm, 4 °C for 20 minutes 
following 4 hours of incubation after IPTG induction. The cell pellets were 
resuspended in 100 mM tris-hydrochloride pH 8.0, 500 mM sodium chloride with 
protease inhibitors tablet (Roche).  
 
 
15 
2.2 Preparing cell pellets  
Cell pellets were completely thawed and sonicated (Ultrasonic processor, Sonics 
Inc.) at 75% amplitude in pulses (5 sec on and 9.9 sec off) with a total sonication 
time of 2.5 minutes. After that the cell lysates were clarified by centrifugation at 
18000 rpm (Sorvall centrifuge, SS-34 rotor) at 4 :C for 30 minutes. The supernatant 
was filtered through 0.45 µm and then 0.2 µm filter (Sarstedt).  
 
2.3 Protein purification 
2.3.1 Immobilized metal ion affinity chromatography (IMAC) 
In the first purification step, IMAC technique was applied where the nickel-
nitriloacetic acid (Ni-NTA) column was employed on an Äkta purifier (column and 
Äkta from GE healthcare). After charging the column with 0.1 M nickel sulfate 
(NiSO4), about 35 ml of filtered cell lysate sample was loaded onto the column. 
IMAC purification was done in 20 mM  tris-hydrochloride, pH 8.0; 500 mM sodium 
chloride (buffer A) and 20 mM tris-hydrochloride, pH 8.0; 500 mM sodium chloride; 
300 mM imidazole (buffer B). After capturing the proteins onto the column, elution 
was done by washing the column with 30 mM imidazole and then a 30-300 mM 
imidazole gradient. The fractions corresponding to the target protein were 
collected, pooled and concentrated using Vivaspin-20 spin column with a MW 
cutoff of 5 kDa (sartorius stedim biotech) at 4 °C. A schematic presentation of 
techniques used in protein purification to oligomers preparation has been stated in 
figure 4.   
 
2.3.2 Size exclusion chromatography (SEC) 
Further purification was achieved through SEC. The concentrated fractions from 
IMAC were loaded onto a Superdex™ 200 PG 16/60 column (GE Healthcare) 
equilibrated with 20 mM tris-hydrochloride, pH8.0; 200 mM sodium chloride at 0.7-
0.9 ml/minute flow rate. The eluted fractions were collected and concentrated on 5 
kDa cut-off Vivaspain-20 column (sartorius stedim biotech).  
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2.4 Separation of Aβ42cc from affibody  
To separate the affibody from Aβ42cc, the eluted fractions from SEC were run on 
another IMAC under denaturing condition. For denaturation, the concentrated 
complex was diluted in guanidinium buffer in a final volume of 25 ml. The 
guanidinium buffer contains, 7 M guanidinium hydrochloride, 0.5 M sodium 
chloride, 0.1 M tris-hydrochloride pH 8.0. After that, the sample was kept at room 
temperature for 30 minutes on tilting table to allow the guanidinium hydrochloride 
to dissolve and complete separation of the complex. The sample was filtered using 
0.2 m filter (Sarstedt).  
 
2.4.1 IMAC under denaturing condition  
25 mL sample (dissolved guanidinium buffer) was loaded onto a Ni-NTA column 
equilibrated with 20 mM tris-hydrochloride pH 8.0; 7 M guanidinium hydrochloride 
at 0.5 ml/minute flow rate. Flow-through was collected and then the column was 
washed with slow imidazole gradient (0-40 mM, 20 min at 1.5 ml/min) followed by 
quick gradient up to 400 mM imidazole.  
 
2.4.2 Confirmation of separation by gel electrophoresis  
Gel electrophoresis (SDS-PAGE) was run to confirm the separation of Aβ42cc from 
the affibody. Denatured IMAC flow through, wash and elution fractions were 
separately run on SDS-PAGE. Before loading on SDS-PAGE, samples were dialyzed 
overnight against 7 M urea. The SDS-PAGE was carried out using the Criterion™ Gel 
system and precast 16.5% tris-tricine gels (Bio-Rad) with 100 mM tris, 100 mM 
tricine and 0.1% SDS (pH 8.25) as cathode buffer and 100 mM tris-hydrochloride 
(pH 8.9) as anode buffer. The gel system was operated at a constant voltage of 120 
V. 10 µl of loading buffer (3X) was added with 20 µl of sample. The loading buffer 
contains 50 mM tris-hydrochloride, 1% SDS, 20% glycerol, 0.23% bromophenol blue, 
and 15 mM heat stabletris-2-carboxyethyl-phosphine (TCEP) reducing agent. 
Samples were then heated at 95 °C for 5 min and approximately 15 µL were loaded 
in each well.  
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Figure 4: Schematic presentation of techniques involved in oligomeric Aβ42cc formation 
including a short description of the most important steps. 
 
2.4.2.1 Staining of the gel   
The gel bands were visualized by silver staining [20]. Initially, the gel was fixed with 
50% ethanol, 12% acetic acid and 0.05% formalin for 1.5 hours. After washing with 
20% ethanol for 20 minutes, the gel was sensitized by 2 minutes incubation in 0.2% 
sodium thiosulphate. After sensitizing, the gel was washed with deionized water 
and then incubated in 0.2% silver nitrate along with 0.076% formalin solution for 20 
minutes. The gel was developed in 6% sodium carbonate, 0.0004% sodium 
thiosulphate and finally the reaction was terminated with 12% acetic acid. A table 
describing all solutions used in silver staining is found in appendix 3.  
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2.5 Aβ42cc oligomers preparation 
After separation on denatured IMAC, Aβ42cc containing fractions were pooled and 
concentrated on 3 kDa cut-off Vivaspain-20 column (sartorius stedim biotech). The 
sample was dialyzed overnight against 20 mM sodium phosphate pH 7.2, 50 mM 
sodium chloride with 5 mM ethylenediaminetetraacetic acid (EDTA) and then 
another dialysis against 20 mM sodium phosphate pH 7.2, 50 mM sodium chloride. 
The sample was then removed from the dialysis bag and treated on water bath at 
60 :C for 10 minutes.  
 
2.5.1 Confirmation of oligomers  
After dialysis, a 200 µl sample was loaded on a Superdex 200™ column (GE 
Healthcare) equilibrated with 20 mM sodium phosphate pH 7.2, 50 mM sodium 
chloride at 0.5-0.7 ml/minute flow rate. The corresponding fractions were collected. 
This analysis was done to confirm the formation of oligomers.  
 
2.6 Capturing of proteins in human serum and CSF 
The main part of this project has been to develop a method for capturing proteins 
in serum and CSF. The serum sample was purchased from 3H Biomedical; Uppsala 
and CSF samples were provided by Prof. Henrik Zetterberg at Department of 
Psychiatry and Neurochemistry at the University of Gothenburg. The protein 
capturing was first started with only serum sample not CSF. Initially, 
immunoprecipitation (IP) was used to capture proteins using Aβ42cc oligomers.  
 
2.6.1 IP with Dynabeads® protein G and 6E10 antibody  
In the first IP setup, we used Dynabeads® protein G (Invitrogen) and Aβ specific 
6E10 antibody (Covance). The experiment was carried out using Invitrogen™ 
protocol and kits (Cat. no.  100.07D). Briefly, 50 µl (a concentration of 30 mg/ml) 
dynabeads was added to 5 µl (concentration, 1 mg/ml) antibody and incubated for 
10 minutes at room temperature to allow antibody binding to dynabeads. After 
washing with 200 µl antibody binding and washing buffer (supplied with 
dynabeads), 100 µl serum and 35 µl Aβ42cc oligomers (The final Aβ42cc 
concentration of the oligomer sample was 0.45 mM) were added and the sample 
was incubated 10 minutes at room temperature with rotation. Following 
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incubation, the complex was washed three times using 200 µl washing buffer each 
time. Finally, the proteins were eluted in SDS-PAGE buffer by heating 10 minutes at 
70 0C. After the first experiment, we run this protocol several times with altered 
protein-ligand concentrations, incubation times and temperatures.  
We also tried the same beads and antibody with an IP protocol from Covance. This 
protocol was the reversed compared to the Invitrogen IP protocol. In the Invitrogen 
protocol, antibody was first added to beads and then the antibody-beads complex 
was incubated with Aβ42cc and serum. But in the Covance protocol, Aβ42cc and 
serum was first added to antibody and then Aβ42cc-serum-antibody complex was 
incubated with beads. 35 µl Aβ42cc and 100 µl serum was added to 5 µl of antibody 
and incubated for 1 hour at 4 0C. After addition of 50 µl dynabeads Protein G, the 
incubation was continued for additional 1 hour. The complex was washed three 
times with washing buffer and for each wash the complex was incubated for 20 
minutes at 4 0C. Elution was done with 10 µl gel loading buffer by heating at 70 0C 
for 3 minutes.  
2.6.2 IP with Dynabeads® M-280 Tosylactivated and 6E10 antibody   
We thought to change the beads and started to use Dynabeads® M-280 
Tosylactivated (Invitrogen, Cat. no. 142.03). The 6E10 antibody was coupled with 
dynabeads® M-280 according to manufacturer instructions. After coupling 25 µl 
(concentration, 20 mg/ml) coupled beads were incubated with 150 µl serum and 35 
µl Aβ42cc for 1 hour at room temperature and then washed three times with PBS, 
0.1% tween (washing buffer, appendix 2). The target proteins were eluted in 10 µl 
SDS-PAGE sample buffer by boiling at 70 0C for 10 minutes.  
 
2.6.3 The developed method 
At this point we excluded the antibody. The tosylactivated beads bind to amino 
groups of ligands by forming amine bond (appendix 2). Therefore, we could couple 
Aβ42cc oligomers directly to the beads instead of the antibody (see section 2.6.2). At 
the same time we also decided to block the beads (to use as control) with another 
protein and used bovine serum albumin (BSA). Later, we instead used glycine to 
block the bead, to remove any interference between blocking agent and the target 
protein. A schematic presentation of the optimized protocol is described in figure 5. 
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Briefly, dynabeads® M-280 tosylactivated was coupled with Aβ42cc oligomers, and 
then the coupled-beads were incubated with serum/CSF.  
 
 
Figure 5. A schematic presentation of the developed capturing method 
 
Initially the beads were prepared according to manufacturer’s instructions. 5 mg of 
beads were added to 100 µg Aβ42cc oligomers along with 0.1 M sodium phosphate 
pH 7.4 (coupling buffer, appendix 2) buffer and incubated overnight at 37 0C on a 
rocking platform to allow covalent binding of Aβ42cc to the beads. The beads-Aβ42cc 
complex was pelleted by using a magnet and supernatant was removed. After 
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adding phosphate buffer seline (PBS) with 0.5% tween (blocking buffer, appendix 2) 
the beads-Aβ42cc complex was incubated for additional 1 hour. After incubation the 
supernatant was removed and the complex was washed with PBS-0.1% tween 
(washing buffer, appendix 2). The coupled beads were stored in same buffer at a 
final concentration of 20 mg/ml. Besides coupling, the beads were blocked with 
glycine to use as control sample. The protocol was the same except that glycine was 
added to bead instead Aβ42cc in the same concentration. 
After coupling/blocking, 25 µl and 40 µl coupled/blocked beads (at a final 
concentration of 20 mg/ml) were added to 150 µl serum and 200 µl CSF, 
respectively. The samples were incubated at 37 0C for 1 hour on a rocking platform. 
Following the incubation, the beads were pelleted by using a magnet and washed 
three times with PBS-0.1% tween. After the final wash the target proteins were 
eluted in 10 µl SDS-PAGE sample buffer by heating to 70 0C for 10 minutes. The 
sample buffer contains 62.5 mM tris-hydrochloride, 25% glycerol,2% SDS,  0.01% 
bromophenol blue, and 15 mM heat stable TCEP. 
2.6.4 Proteins analysis by gel electrophoresis  
SDS-PAGE gel electrophoresis was run to analyze the proteins captured by the 
different capturing methods. After elution by SDS-PAGE sample buffer, 10 µl 
samples were loaded in each well. The operation was carried out with Criterion™ 
Gel system and 4-20% gradient gels (Bio-Rad). The gel system was operated at a 
constant 200 V voltage with 1X SDS running buffer for around 45 minutes. SDS 
running buffer contains, 25 mM tris, 192 mM glycine and 0.1% SDS, pH 8.3.  
 
2.6.4.1 Staining of the gel 
A major focus of this project was to develop a capturing method to capture enough 
quantity of protein from serum and CSF. When we first started to develop the 
method, we stained the gel in silver staining. Silver staining procedure is already 
described in section 2.4.2.1. Since the silver staining is not compatible with mass 
spectrometry, later the gels were stained in Acquastain. In acquastain method, the 
gel was put in a plastic box and aquastain solution (Bulldog Bio, Inc) was poured 
upon the gel. The gel was kept in solution until the bands were clearly visualized.  
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2.7 Sampling for MS 
The MS analysis of the captured proteins was carried out at the SciLifeLab MS- 
platform, Uppsala University. We have prepared the samples for MS in our lab and 
handled them to the SciLifeLab. Briefly, selected bands were cut and placed into 
separate eppendorf tubes. The gelbands were washed three times with 30% 
ethanol for 30 minutes. Then the gelbands were incubated in 10 mM dithiothreitol 
for 1 hour at 50 0C and then again incubated in 55 mM iodoacetamide solution for 1 
hour in darkness. The gelbands were washed in 25 mM ammonium hydrogen 
carbonate for 5 minutes, followed by 5 minutes incubation in acetonitrile. After 
drying the gelbands in a SpeedVac® for 15 minutes, the proteins in the gelbands 
were digested by incubation in 12 ng/µl trypsin in 25 mM ammonium hydrogen 
carbonate for 1 hour at room temperature. The solution was discarded and the 
gelbands were incubated in 25 mM ammonium hydrogen carbonate at 37 0C, 
overnight in darkness. Solvents from each gelbands were collected in new tubes. 
After sonication of the gelbands in 60% acetonitrile, 5% formic acid for 5 minutes, 
the solutions from the sonicated gelbands were pooled with the previous 
corresponding fractions. Finally, the samples were dried in SpeedVac®. 
 
2.8 MS analysis and database search 
The samples were loaded onto a MTP 384 ground steel target using the dried 
droplet technique and the matrix used was α-cyano-4-hydroxycinnamate. Mass 
spectra were recorded using an Ultraflex II MALDI TOF MS (Bruker Daltonics, 
Bremen, Germany) in positive mode. Peptide mass mapping was performed using 
the Mascot search engine (experimental information of this section was provided 
by the SciLifeLab MS-platform, Uppsala).  
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3. Results  
3.1 Protein expression and purification 
The expression vector pACYCDuet-1 had already been constructed with genes for 
Aβ42cc and ZAβ3 and transformed into bacterial cells. The Aβ42cc:ZAβ3 complex was 
overexpressed using existing protocols [8]. The cell culture was allowed to grow 4 
hours after IPTG induction and the protein was obtained in the soluble fractions of 
cell lysates.  
 
Two liquid chromatography techniques were applied to purify Aβ42cc:ZAβ3 complex. 
The protein complex was first purified by using IMAC purification and then polished 
by SEC. In the Aβ42cc:ZAβ3 complex, ZAβ3 was tagged with six-histidines. During 
loading of the sample, Aβ42cc:ZAβ3 complex was bound onto the nickel column while 
other cellular proteins pass through it. The first absorbance peak in figure 6A 
corresponds to those proteins that pass through the column while histidine-tagged 
proteins are capturing onto the matrix. The second and third peaks are wash 
fractions using 30 mM and 300 mM imidazole respectively. The third peak (in the 
dotted frame in figure 6A) is the elution of the Aβ42cc:ZAβ3 complex. Whereas the 
second peak indicates that proteins that bind weakly to the column are eluted. 
After the IMAC purification, the fractions corresponding to the elution of the 
Aβ42cc:ZAβ3 complex were pooled and concentrated. After concentration the 
absorbance value was OD280 = 3.92 AU.   
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Figure 6. Elution profiles of Aβ42cc:ZAβ3 complex on IMAC and SEC   
(A) An IMAC purification of Aβ42cc:ZAβ3 with Ni-NTA column in 20 mM tris-hydrochloride, pH 
8.0; 500 mM sodium chloride buffer and eluted with a gradient of 0-300 mM imidazole. 
Chromatogram showing protein absorbance at 280nm (blue) and 0-300 mM imidazole 
gradient (green). The third peak corresponds to Aβ42cc:ZAβ3 (uses around 90% of final 
imidazole concentration, in the dotted frame).  
(B) Polishing of Aβ42cc:ZAβ3 with Superdex™ 200 PG 16/60 column in 20 mM tris-
hydrochloride, pH 8.0; 200 mM sodium chloride. The second peak (in dotted frame) 
corresponds to Aβ42cc:ZAβ3  
Following IMAC, SEC was run to obtain increased purity of the Aβ42cc:ZAβ3 complex 
and to remove imidazole from the sample. Proteins with higher molecular weight 
are expected to elute first (first peak in figure 6B). The second peak in figure 6B 
corresponds to Aβ42cc:ZAβ3 complex. All fractions that correspond to the Aβ42cc:ZAβ3 
A280(mAU) %B 
Elution volume (mL) 
Elution volume (mL) 
A280(mAU) 
A. 
 
B. 
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complex were collected and concentrated up to OD280 = 4.57 AU.     
3.2 Separation of the protein complex  
Protein samples from SEC were diluted in guanidinium buffer (see section 2.4) and 
then subjected to another IMAC step. Guanidinium hydrochloride is a common 
chemical denaturant used in for protein denaturation [21,22]. From the IMAC run, 
flow through, wash and elution fractions were collected separately. Since Aβ42cc is 
not his-tagged and separated from the his-tagged ZAβ3 protein, it passes through the 
column during sample loading and elutes with the flow-through (the first two peaks 
in figure 7A, in the dotted frame). IMAC wash fractions using 40 mM and 400 mM 
imidazole (third and fourth peaks in figure 7A respectively) contain ZAβ3 affibody, as 
it binds to the column and elutes by the imidazole gradient.  
3.2.1 Analysis of the separation  
The fractions containing Aβ42cc were identified by SDS-PAGE (16.5% tris-tricine gel 
described in section 2.4.2) analysis. The flow-through fractions give band at 6 kDa 
(figure 7B, lane: 2-5; in the dotted frame), indicating pure Aβ42cc. IMAC wash 
fractions using 40 mM imidazole give weak bands at approximately 8 kDa (figure 7B, 
lane: 6-7), indicating the presence of affibody. Eluted fractions using 400 mM 
imidazole also contains affibody, as indicated by a relatively clear band around 8 
kDa (figure 7B, lane: 8-9). The bands at 15 kDa are most likely affibody dimer.   
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Figure 7. Separation of Aβ42cc from affibody  
(A) Elution profile of Aβ42cc:ZAβ3 under denaturing condition. Ni-NTA column was used with 
20 mM tris-hydrochloride pH 8.0; 7 M guanidinium hydrochloride buffer and eluted with 
a gradient of 0-400 mM imidazole. Chromatogram showing protein absorbance at 280 
nm (blue) and 0-400 mM imidazole gradient (green). The first two peaks correspond to 
Aβ42cc (in the dotted frame), whereas gradient eluted fractions corresponds to ZAβ3. 
(B) SDS-PAGE analysis of Aβ42cc IMAC fractions with 16.5% tris-tricine gel. Lane 1 and 10: 
molecular size marker. Lane 2-5: flow through fractions (fractions from first two peaks in 
figure 7A). Lane 6 and 7: IMAC wash fractions (40 mM imidazole, fractions from third 
small peak in figure 7A). Lane 8 and 9: IMAC wash fractions (400 mM imidazole, fractions 
from fourth peak in figure 7A). 
 
%B A280(mAU) 
A. 
 
Elution volume (mL) 
B. 
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3.3 Aβ42cc oligomers preparation 
Aβ42cc containing fractions from denatured IMAC (first and second peak in figure 
7A, lane 2-5 in figure 7B) were collected for oligomer formation via renaturation. 
Fractions were pooled and dialyzed against sodium phosphate buffer at pH 7.2 (see 
section 2.5). Aβ42cc oligomers formed spontaneously during the dialysis [17]. 
3.3.1 Confirmation of oligomers  
After dialyzes, samples were loaded on a Superdex 200™ column and the 
chromatogram was compared with the expected elution volume for monomer, 
dimer, trimer (figure not shown). The comparison confirms the formation of Aβ42cc 
oligomers. Moreover, there was one peak (figure 8, in dotted frame) in the elution 
profile, which indicates homogenous sample. The final Aβ42cc concentration of the 
oligomer sample was 0.45 mM.  
 
 
Figure 8. Elution profile of Aβ42cc oligomers on SEC  
  
3.4 Development of the capturing method 
The main goal of the project was to develop an effective capturing method to 
capture proteins from human serum and CSF that interact with neurotoxic Aβ42cc 
oligomers. At the beginning of method development, two IP protocols: Dynabeads® 
protein G and Dynabeads® M-280 Tosylactivated were used. Many changes 
A280(mAU) 
Elution volume (mL) 
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including dynabeads type, antibody, ligand-proteins concentrations, incubation 
times, temperatures, washing steps and elution steps have been done during 
capture method developing.  
3.4.1 Proteins capturing in serum  
Initially, the development was carried out using serum samples. In the very first 
step of the development, dynabeads® protein G and 6E10 antiboby were used and 
the Aβ specific 6E10 antibody was allowed to bind with dynabeads protein G. The 
antibody-bead complexes were incubated with serum and Aβ42cc and then eluted 
by SDS-PAGE sample buffer. We did not find any unique bands in Aβ42cc samples 
(lane 1 and 2 in figure 9A) compared to the control (lane 3 in figure 9A). After the 
first experiment, we set-up several additional experiments with same type of beads 
but with different ligand-protein concentrations, temperatures, and incubation 
times (figure not shown) but the results were not promising; because no proteins 
were fished out with Aβ42cc. We also used a reverse protocol from Covance where 
Aβ42cc and serum were first incubated with the 6E10 antibody and then 
dynabeads® protein G was added to the complex. But the results were disappointed 
us again, as no proteins were fished out with Aβ42cc.  
Then we decided to change binding strategy i.e. use of different type of beads to 
bind the antibody. Dynabeads® M-280 tosylactivated beads were chosen. For the 
first time we noticed some bands that were unique for the Aβ42cc samples (lane 2, 
3, and 4 in figure 9B, marked in dotted frame) and not found in the control (lane 1 
and 5 in figure 9B). After this experiment we decided to exclude the antibody, 
because the tosylactivated bead can bind to amino group of any protein by forming 
amine bond. So it is possible to couple the Aβ42cc oligomers directly to the beads. 
The beads have activated tosyl groups that are cleaved in the presence of amino 
groups while the other part on the bead binds to amino groups of ligand by forming 
amine bond (appendix 2). At the same time we also blocked the beads (lane 4 in 
figure 9C) with bovine serum albumin (BSA) for using as control. In this experiment 
we found several unique bands for Aβ42cc sample (lane 1 in figure 9C) that are not 
present in control sample (lane 4 in figure 9C). 
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Figure 9. SDS-PAGE analysis of proteins captured in serum  
 
(A) Dynabeads® protein G and 6E10 antibody (gel stained with silver staining). Lane 1 and 2: 
dynabeads-antibody complex, Aβ42cc and serum. Lane 3: dynabeads-antibody complex and 
serum (control). Lane 4-6: Supernatants from last washing step of 1, 2, and 3 respectively.  
(B) Dynabeads® M-280 Tosylactivated beads and 6E10 antibody (gel stained with silver staining). 
Lane 1: dynabeads-antibody complex and serum (control, without Aβ42cc). Lane 2-4: dynabeads-
antibody, Aβ42cc and serum (different concentrations). Lane 5: dynabeads-antibody and Aβ42cc 
(control, without serum). Lane 6-10: Supernatants from last washing step of 1, 2, 3, 4 and 5 
respectively.  
(C) Dynabeads® M-280 Tosylactivated beads conjugated with Aβ42cc (gel stained with acquastain). 
Lane 1: Aβ42cc conjugated beads and serum. Lane 2: Aβ42cc conjugated beads (without serum). 
Lane 3: BSA blocked beads. Lane 4: BSA blocked beads, Aβ42cc and serum.  
(D) Dynabeads® M-280 Tosylactivated beads conjugated with Aβ42cc (gel stained in acquastain). 
Lane 1 and 2: Aβ42cc conjugated beads and serum. Lane 3: Glycine blocked beads and serum. Gel 
bands numbed as 1-7 in lane 1 means those bands were cut for MS analysis.  
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As the silver staining method is not compatible to MS, we decided to stain the gel 
with acquastain, which is more suitable for MS analysis. However, the lower 
sensitivity of this detection method posed a challenge to visualize proteins on the 
gel. To overcome this problem we paid attention to elute more proteins and we 
used different volume of gel loading buffer. Another challenge for us was to figure 
out whether or not the proteins are binding specifically to Aβ42cc ligand or to the 
bead surface. We tried mild elution at low pH buffer (figure not shown), that 
showed no protein elutes at low pH buffer.  
Now the protocol seemed to be working. At this point we decided to use glycine to 
block the beads instead BSA to avoid BSA interference with Aβ42cc or serum or CSF, 
if there are any. It seems glycine blocked beads (comparing lane 4 in figure 9C with 
lane 3 in figure 9D) is quite better than BSA blocked beads, as no binding proteins 
was found in the samples with glycine blocked bead. For the final experiment, we 
again made some changes in temperatures and incubation times. We found several 
unique bands in the Aβ42cc samples (lane 1 and 2 in figure 9D) that were not 
present in the control sample with glycine blocked beads (lane 3 in figure 9D). The 
bands around 15 kDa and other bands around 6 kDa most likely originates from the 
Aβ42cc itself, confirming its attachment to the beads and these two bands are 
present in all Aβ42cc samples in all experiment. The oligomers are coupled to bead 
and then contact to target protein, in the elution step this oligomer are denatured 
and dissociates as we have bands for Aβ42cc in the gel. The unique bands for Aβ42cc 
sample (numbered as 1-7 in lane 1 in figure 9D) were cut and submitted for MS 
analysis.  
3.4.2 Proteins capturing in CSF 
For capturing proteins in CSF the same developed method was used. Six CSF 
samples have been investigated of which three from AD patients and other three 
from healthy individuals. Besides the identification of binding proteins we also 
wanted to figure out the differences of captured proteins among all six samples and 
also differences compared to proteins captured in serum. We found several bands 
in the Aβ42cc samples (all odd numbers lane in figure 10) and there are almost no 
bands in control samples (all even numbers lane in figure 10). From this gel, five 
protein bands (numbered as 1-5 in different lanes in figure 10) were submitted for 
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MS analysis.  
 
3.4.3 Comparisons of proteins captured in CSF and serum samples 
All samples display bands around 6-7 kDa and 15 kDa, generated from Aβ-itself 
indicating its attachment to the beads. All three non-AD (lane 1, 3 and 5 in figure 
10) and two of AD samples (lane 7 and 9 in figure 10) gives clear bands around 25 
kDa whereas the third AD sample (lane 11 in figure 10) gives a week band at the 
corresponding size. Bands with the same MW were also present in serum samples 
(figure 9D). Protein bands at 35 kDa is present in all samples (all odd number lanes 
in figure 10) and that was also found in the serum sample, but in the serum sample 
there were two bands in this region. Potentially, there are also two bands around 
35-37 kDa in CSF samples but not visible due to low protein concentration. 
 
 
Figure 10. SDS-PAGE analysis of proteins captured in CSF samples  
Lane 1,3 and 5: Aβ conjugated beads and CSF samples from three non-AD individuals. Lane 7, 
9 and 11: Aβ conjugated beads and CSF samples from three AD patients. Even number lanes 
are controls (glycine blocked beads) for each of the samples.  
 
Two non-AD (lane 1 and 3 in figure 10) and two AD (lane 7 and 9 in figure 10) 
samples give some week protein bands around 60-70 kDa and some bands were 
also found in the serum sample in the same region but their MW were quite higher 
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(in between 65-80 kDa). Apparently, two non-AD (lane 3 and 5) and one AD (lane 9 
in figure 10) give bands about 80 kDa, comparable to serum sample as there was 
also band about 80 kDa. It is interesting that several protein bands in CSF samples 
are observed at approximately the same MW as in the serum sample.  
 
3.5 MS analysis of proteins captured in serum  
From the SDS-PAGE of serum, seven samples (selected bands from lane 1 in figure 
9D) were extracted for MS analysis and proteins from six of these samples were 
successfully identified. The proteins were identified according to table 1.  
Table 1. Proteins in serum identified by MS analysis  
Sample Numbersª Indentified protein  
        1 Apolipoprotein A-I 
        2 Apolipoprotein E 
        3 Apolipoprotein E 
        4 Apolipoprotein A-VI 
        5 Vitronectin  
        6 No protein Identified  
        7 Antithrombin III  
   ª corresponds to the number in lane 1 in figure 9D.  
No protein was identified for sample 6 (gelbands numbered as 6 in lane 1 in figure 
9D), although the gel band was clearly visible and the protein should be there. 
Potentially something went wrong at the sample preparation step.  
 
3.6 MS analysis of proteins captured in CSF 
Five samples (bands numbered as 1-5 in figure 10) from the SDS-PAGE of the CSF 
samples were submitted for MS analysis. Proteins from four of the five samples  
Table 2. Proteins in CSF identified by MS analysis  
Sample Numbersº Indentified protein  
        1 Apolipoprotein A-I 
        2 Apolipoprotein E 
        3 No protein Identified 
        4 Clusterin 
        5 Gelsolin   
   º corresponds to gel band number in figure 10.  
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were successfully identified (table 2). No protein was found in sample 3 (gel band 
numbered as 3 in lane 1 in figure 10), possibly due to error at the preparation step.  
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4. Discussions 
4.1 Proteins captured in serum  
Among the six identified proteins that were fished out with Aβ42cc from serum, four 
protein bands (bands at approximately 25 kDa, 30 kDa, 35 kDa and 45 kDa in figure 
9D) have been identified as apolipoproteins (apolipoprotein A-I, A-IV and E) and two 
of them are identified as same protein (Apolipoprotein E). The other two proteins 
are Vitronectin (at 64 kDa, lane 1 in figure 9D) and Antithrombin III (at 80 kDa, lane 
1 in figure 9D). Associations of these proteins in AD have not been extensively 
reported but apolipoproteins including apolipoprotein E (Apo E) and apolipoprotein 
A-IV (Apo A-IV) have been reported to play role in amyloid fibril formation in 
atherosclerosis [23]. 
Apolipoprotein A-I (Apo A-I) acts as cholesterol transporter and inflammation 
regulator, has been reported at decreased level in serum and CSF with a variety of 
neurodegenerative diseases including AD, PD and down syndrome [24]. Apo A-I is 
also found in arterial plaques of atherosclerosis [25,26,27].  
Among all apolipoproteins, Apo E with its E4 isoform has frequently been reported 
as risk factor for late-onset AD [28,29]. The E4 isoform is a cholesterol-carrying 
protein [30] linked to sleep apnea, a frequent condition in AD [31] and may underlie 
in disease pathology. But the exact role of Apo E in AD has not been extensively 
reported [32,33].  
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Apo A-IV, another typical apolipoprotein in plasma and CSF [34,35], has been 
reported to play role in amyloidosis [36] but the pathologic role in AD still unknown 
[37]. The next protein on the identified proteins list is vitronectin, a glycoprotein 
that has been found in amyloid deposits in senile plaques [38,39]. And the last one 
on the list, Antithrombin III, has been identified in AD serum but interaction with Aβ 
oligomer has not been reported as for other identified proteins [40].    
4.2 Proteins captured in CSF 
Four proteins in different CSF samples have been identified (table 2). Two of the 
four identified proteins are reported as Apo A-I (band about 25 kDa in lane 5 in 
figure 10) and Apo E (band about 35 kDa in lane 7 in figure 10). These two proteins 
were also indentified in serum (see section 3.5). Apo A-I and Apo E proteins are 
abundant in CSF [37]. The possible role/interaction of these proteins in/with AD is 
already discussed in section 4.1.  
Clusterin is an enigmatic glycoprotein [41]. The protein is also known as 
apolipoprotein-J [42]. Clusterin is capable of interacting with broad spectrum of 
molecules and is found in amyloid plaques and cerebrovascular deposits [43]. 
Moreover, the protein is involved in apoptotic cell death [41], so it is not 
unexpected to find an interaction of clusterin with Aβ42cc oligomer and that 
happened in this study. In the pathological condition, clusterin is considered as 
amyloid-associated protein [44].  
The next protein that was fished out with Aβ42cc from CSF is Gelsolin. It has been 
reported to act in protein misfolding including amyloid fibril formation of AD [45], 
but the pathological role is not clear [46] and further studies are required.  
4.3 Concluding remarks  
To date, no interactions between Aβ42cc oligomers and other proteins have been 
reported. This project has reported such interactions for the first time. The 
developed capturing method worked nicely for capturing proteins in both serum 
and CSF but still it might need some modifications for capturing proteins in CSF, 
since the protein concentration in CSF is lower than in serum and that caused a 
problem to visualize protein bands in CSF experimental gel.  
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In the future, additional techniques could be used for better understanding of the 
Aβ42cc oligomers-serum/CSF protein interactions. Surface Plasmon Resonance (SPR) 
could be applied, that will give information about binding specificity, affinity, 
kinetics as well. For SPR study the protein that are fished out with Aβ42cc can be 
recovered from SDS-PAGE gel or the proteins can be recombinantly express as we 
have the protein details now, including sequence and MW. Circular dichroism (CD) 
spectroscopy technique could be employed to study protein stability. This 
experiment will provide information while the identified proteins are interacting 
with Aβ42cc oligomers, what type of conformational change occurs there, and 
interaction patterns as well. The identified proteins could be individually express to 
study their structures.  
Another approach could be co-expression of Aβ42cc peptide with the identified 
proteins and purification of the complex. Following the expression and purification, 
structural studies could be conducted by x-ray crystallography or NMR. This 
approach will give opportunity to study the interaction mechanism in more detail. 
The findings will improve the knowledge about Aβ neurotoxicity and therefore 
mechanisms behind AD.  
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Popular science summary  
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. The 
prevalence of AD is rapidly increasing and more than 100 million elderly are 
expected to have AD by 2050. Despite the extensive research of the last few 
decades, we do not have the mechanism details of AD in our hands. The amyloid 
hypothesis guides us that the oligomerization and aggregation of Aβ peptides have 
been linked to the pathogenesis of AD. An important hypothesis today is that 
neurotoxic oligomeric Aβ aggregates are responsible for cell death and there might 
be interactions between Aβ oligomers and other critical cellular components that 
lead Aβ neurotoxicity. The project was aimed at identifying which proteins that 
interact with Aβ oligomers in serum and cerebrospinal fluid (CSF). 
The work plan of this project has been divided into two parts where one has been 
to produce pure neurotoxic Aβ42cc oligomers. An engineered Aβ (Aβ42cc) was used 
in this project. The double cysteine mutated Aβ (Aβ42cc) was produced in E. coli by 
co-expression with ZAβ3 affibody. The Aβ42cc:ZAβ3 protein complex has been 
overexpressed and then purified using immobilized metal ion affinity 
chromatography (IMAC) and size exclusion chromatography (SEC). After 
purification, the complex was separated by another IMAC under denaturing 
condition *8+. Aβ42cc oligomer has been produced by dialysis of peptide in 
denaturing solution against sodium phosphate buffer at pH 7.2. The other part has 
been to study the interaction of Aβ42cc oligomers with other proteins in human 
serum and CSF. The main focus of this second part has been to develop a protocol 
to capture protein ligands in human serum and CSF. An effective capturing method 
has been developed and applied to capture proteins in serum and CSF. Then the 
captured proteins have been separated by gel electrophoresis and analyzed by 
mass spectrometry (MS). Five proteins in serum have been reported as 
Apolipoprotein A-I, Apolipoprotein E, Apolipoprotein A-IV, Vitronectin and 
Antithrombin III. In the case of identifying and comparing binding proteins in CSF, 
six different samples have been used of which three are from AD patients and 
another three are from non-AD individuals. From different CSF samples four 
proteins have been identified as Apolipoprotein A-I, Apolipoprotein E, Clusterin and 
Gelsolin.  
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Many studies suggest the presence of other proteins in amyloid plaque of AD but 
the pathologic role is still unknown. From this study, we now know that there are 
also interactions between certain proteins and Aβ oligomers. The findings of this 
project will improve the knowledge about the properties of Aβ aggregates and the 
related toxicity mechanism and therefore improve the understanding of the 
mechanisms behind the onset and progress of AD. Moreover, the developed 
capturing technique could be helpful to study other neurodegenerative diseases 
where protein aggregation is a fact, including Parkinson’s disease, Huntington’s 
disease and frontotemporal dementia.   
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Appendices  
Appendix 1 
  Table 1: Preparation of 1 liter of TB medium 
Ingredients Amounts 
Tryptone 12 g 
 Yeast extract 24g 
Glycerol 4 ml 
 
 
  Table 2: 1 M (10x) potassium phosphate buffer: 0.17 M KH2P04 and 0.72 M K2HP04 
Ingredients Amounts 
KH2P04 23.13 g 
 K2HP04 125.40 g 
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Appendix 2 
  Table 1: Buffers used in developed captured method 
Buffers name  Buffers compositions  
Coupling buffer 0.1 M Na-phosphate buffer pH 7.4 
 
 
 
  Blocking buffer PBS pH 7.4 with 0.5% Tween 
  Washing buffer PBS pH 7.4 with 0.1% Tween 
   
 
 
 
Figure 1. The Tosylactivated beads have activated a tosyl group that cleaves in the 
presence of amion group while the other part on the bead binds to amino groups of 
ligand by forming amine bond. 
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Appendix 3 
Table 1: Silver staining solutions [20] 
Solutions Name Ingredients 
Fixation solution 50% ethanol, 12% acetic acid, 0.05% formalin 
Wash solution 20% ethanol 
Senzitizing solution 0.02% sodium thiosulphate 
Staining solution 0.2% silver nitrate, 0.076%formalin 
Development solution 6% sodium carbonate ,0.0004% sodium thiosulphate 
Termination solution 12% acetic acid 
  
 
